Tech Company Financing Transactions
Aura Biosciences Funding Round
Aura Biosciences closed a $4.5 million Series B financing round on 9/8/2011. Investors included private investors.
Transaction Overview
Company Name
Announced On
9/8/2011
Transaction Type
Venture Equity
Amount
$4,500,000
Round
Series B
Investors
Proceeds Purpose
The funds will be used to build Aura's infrastructure and team, and to move toward the company's first investigational new drug (IND) application before the end of 2012.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
85 Bolton St.
Cambridge, MA 02140
USA
Cambridge, MA 02140
USA
Phone
Website
Email Address
Overview
Aura Biosciences is developing a new class of therapies to target and selectively destroy tumor cells. Its lead program in ocular melanoma, developed under a CRADA with the National Cancer Institute (NCI), has been granted orphan drug status by the US Food and Drug Administration.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Elisabet de los Pinos
Chief Financial Officer
Julie Feder
Chief Medical Officer
Cadmus Rich
Browse more venture capital transactions:
Prev: 9/8/2011: Striiv venture capital transaction
Next: 9/8/2011: AlertEnterprise venture capital transaction
Share this article
Where The Data Comes From
We record all VC transactions involving tech companies. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs